Tom D.J. Smilde

3.4k total citations · 1 hit paper
30 papers, 2.4k citations indexed

About

Tom D.J. Smilde is a scholar working on Cardiology and Cardiovascular Medicine, Nephrology and Surgery. According to data from OpenAlex, Tom D.J. Smilde has authored 30 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Cardiology and Cardiovascular Medicine, 12 papers in Nephrology and 4 papers in Surgery. Recurrent topics in Tom D.J. Smilde's work include Heart Failure Treatment and Management (11 papers), Dialysis and Renal Disease Management (10 papers) and Blood Pressure and Hypertension Studies (8 papers). Tom D.J. Smilde is often cited by papers focused on Heart Failure Treatment and Management (11 papers), Dialysis and Renal Disease Management (10 papers) and Blood Pressure and Hypertension Studies (8 papers). Tom D.J. Smilde collaborates with scholars based in Netherlands, Australia and Greece. Tom D.J. Smilde's co-authors include Dirk J. van Veldhuisen, Adriaan A. Voors, Hans L. Hillege, Gerjan Navis, Kevin Damman, Folkert W. Asselbergs, John G.F. Cleland, Wiek H. van Gilst, Wim van der Bij and B. Daan Westenbrink and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and European Heart Journal.

In The Last Decade

Tom D.J. Smilde

30 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized, Double-Blind, Placebo-Controlled, Multicentre Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients with Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF)

2020 295 citations Kevin Damman, Joost C. Beusekamp et al. European Journal of Heart Failure profile →

Peers

Tom D.J. Smilde

CCM

NEPHR

PRM

EDM

SURGE

H. L. Hillege Netherlands

Jan Biegus Poland

Ernesto Paoletti Italy

Michael Kapeliovich Israel

Petra Nijst Belgium

Kayo Shinohara Japan

David Brosh Israel

Robert S. Kramer United States

Marcel Lebel Canada

Eileen O’Meara Canada

H. L. Hillege Netherlands

Tom D.J. Smilde

1.4k ×0.9

CCM

416 ×0.5

NEPHR

485 ×0.8

PRM

192 ×0.6

EDM

212 ×0.7

SURGE

Citations per year, relative to Tom D.J. Smilde Tom D.J. Smilde (= 1×) peers H. L. Hillege

Countries citing papers authored by Tom D.J. Smilde

Since Specialization

Citations

This map shows the geographic impact of Tom D.J. Smilde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom D.J. Smilde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom D.J. Smilde more than expected).

Fields of papers citing papers by Tom D.J. Smilde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom D.J. Smilde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom D.J. Smilde. The network helps show where Tom D.J. Smilde may publish in the future.

Co-authorship network of co-authors of Tom D.J. Smilde

This figure shows the co-authorship network connecting the top 25 collaborators of Tom D.J. Smilde. A scholar is included among the top collaborators of Tom D.J. Smilde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom D.J. Smilde. Tom D.J. Smilde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Damman, Kevin, Joost C. Beusekamp, Eva M. Boorsma, et al.. (2020). Randomized, Double-Blind, Placebo-Controlled, Multicentre Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients with Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF). European Journal of Heart Failure. 22(4). 713–722. 295 indexed citations breakdown →

Schroten, Nicolas F., Kevin Damman, Mattia A. E. Valente, et al.. (2015). Long-term changes in renal function and perfusion in heart failure patients with reduced ejection fraction. Clinical Research in Cardiology. 105(1). 10–16. 19 indexed citations

Damman, Kevin, Dirk J. van Veldhuisen, GJ Navis, et al.. (2010). Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart. 96(16). 1297–1302. 159 indexed citations

Damman, Kevin, Dirk J. van Veldhuisen, Gerjan Navis, et al.. (2009). Tubular Damage Is Common and Associated With Reduced Survival in Patients With Chronic Heart Failure. Data Archiving and Networked Services (DANS). 1 indexed citations

Smilde, Tom D.J., Kevin Damman, Pim van der Harst, et al.. (2008). Differential associations between renal function and “modifiable” risk factors in patients with chronic heart failure. Clinical Research in Cardiology. 98(2). 121–129. 106 indexed citations

Damman, Kevin, et al.. (2007). Worsening renal function and prognosis in heart failure; a meta-analysis of published studies. UCL Discovery (University College London). 2 indexed citations

Voors, Adriaan A., Casper G. Schalkwijk, Jean L.J.M. Scheijen, et al.. (2007). Clinical and prognostic value of advanced glycation end-products (AGEs) in chronic heart failure. Data Archiving and Networked Services (DANS). 1 indexed citations

Hartog, Jasper W.L., Adriaan A. Voors, Casper G. Schalkwijk, et al.. (2007). Abstract 2389: Clinical and Prognostic Value of Advanced Glycation End-products (AGEs) in Chronic Heart Failure. Circulation. 116. 2 indexed citations

Damman, Kevin, Gerjan Navis, Tom D.J. Smilde, et al.. (2007). Decreased Cardiac Output, Venous Congestion and the Association with Renal Impairment in Patients with Cardiac Dysfunction. European Journal of Heart Failure. 9(9). 872–878. 352 indexed citations

10.

Smilde, Tom D.J., Mike W. Zuurman, Hans Hillege, et al.. (2007). Renal Function Dependent Association of AGTR1 Polymorphism (A1166C) and Electrocardiographic Left-Ventricular Hypertrophy. American Journal of Hypertension. 20(10). 1097–1103. 16 indexed citations

11.

Damman, Kevin, Gerjan Navis, Adriaan A. Voors, et al.. (2007). Worsening Renal Function and Prognosis in Heart Failure: Systematic Review and Meta-Analysis. Journal of Cardiac Failure. 13(8). 599–608. 451 indexed citations

12.

Hartog, Jasper W.L., Adriaan A. Voors, Casper G. Schalkwijk, et al.. (2007). Clinical and prognostic value of advanced glycation end-products in chronic heart failure. European Heart Journal. 28(23). 2879–2885. 80 indexed citations

13.

Perik, Patrick J., Elisabeth G.E. de Vries, Jourik A. Gietema, et al.. (2006). Serum HER2 Levels are Increased in Patients with Chronic Heart Failure. European Journal of Heart Failure. 9(2). 173–177. 36 indexed citations

14.

Damman, Kevin, Tom D.J. Smilde, Adriaan A. Voors, et al.. (2006). Impaired renal function is not only related to decreased cardiac output but also to increased venous pressure in patients with cardiac dysfunction. Circulation. 114(18). 94–94. 4 indexed citations

15.

Smilde, Tom D.J., et al.. (2005). Difference in long-term prognostic value of renal function between ischemic and non-ischemic mild heart failure. International Journal of Cardiology. 107(1). 73–77. 5 indexed citations

16.

Smilde, Tom D.J., Gerard C.M. Linssen, Thomas Machnig, et al.. (2005). Influence of renal dysfunction on the pharmacokinetics of the selective Na+/H+ exchange inhibitor EMD 87 580 in patients with chronic heart failure. International Journal of Clinical Pharmacology and Therapeutics. 43(11). 507–516. 3 indexed citations

17.

Meer, Peter van der, Adriaan A. Voors, Erik Lipšic, et al.. (2004). Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. Journal of the American College of Cardiology. 44(1). 63–67. 157 indexed citations

18.

Meer, Peter van der, Adriaan A. Voors, Erik Lipšic, et al.. (2004). 1145-121 Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. Journal of the American College of Cardiology. 43(5). A221–A222. 2 indexed citations

19.

Smilde, Tom D.J., Hans L. Hillege, Adriaan A. Voors, Peter H.J.M. Dunselman, & Dirk J. van Veldhuisen. (2004). Prognostic importance of renal function in patients with early heart failure and mild left ventricular dysfunction. The American Journal of Cardiology. 94(2). 240–243. 38 indexed citations

20.

Smilde, Tom D.J., Hans L. Hillege, Gerjan Navis, et al.. (2004). Impaired renal function in patients with ischemic and nonischemic chronic heart failure: association with neurohormonal activation and survival. American Heart Journal. 148(1). 165–172. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact